A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)

Trial Profile

A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Lymphoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms KEYNOTE-051
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Dec 2017 Planned primary completion date changed from 2 Jan 2019 to 1 Sep 2022.
    • 22 Nov 2017 Planned number of patients changed to 311.
    • 20 Sep 2017 protocol was amended to change in the treatment arms and change in the endpoints.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top